TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Lapatinib (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms TRYHARD
- 04 Oct 2023 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Primary endpoint (Progression-Free survival) has not been met as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology